Asymmetrex recently received a $0.42 million award from the NIH-National, Heart, Lung, and Blood Institute to support technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. Tech Company News reached out to Asymmetrex Director James L. Sherley to interview him about this achievement and how the company plans to use the funds.
“In our recent published report, we established proof of concept with a few compounds. With the SBIR award, we will evaluate sufficient compounds to know quantitatively how well our test predicts not just tissue stem cell toxicity, but actual chronic organ failure in patients.”
Read the full interview here.